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MicroRNAs (miRs) are small non-protein encoding RNAs that post-transcriptionally regulate gene 
expression by inducing mRNA degradation or translational repression of their targets. The role of 
miRs in regulating cellular processes such as DNA replication and repair is a subject of intense 
investigation, particularly as aberrant miR expression has been associated with cancer. As part of a 
cell-based approach to identify miRs that modulate the DNA repair response, postdoctoral fellow Dr. 
Yemin Wang and colleagues in the Human Biology Division screened 810 human miR mimics for 
candidates that altered the accumulation of phosphorylated histone H2AX (γH2AX) in response to 
ionizing radiation (IR), as γH2AX recruits signaling and repair proteins to sites of DNA damage. They 
identified two such miRs, miR-138 and miR-542-3p, and discovered that the more potent miR-138 
directly targets H2AX mRNA, thereby reducing both H2AX mRNA and H2AX and γH2AX protein 
expression levels. MiR-138 is highly conserved, highly expressed in brain tissues and originates 
from 2 genomic precursors (miR-138-1 and miR-138-2), both of which were shown to reduce H2AX 
expression. Indeed, when Wang et al. examined normal brain tissue, 10 glioma cell lines and 26 
glioblastoma tissue samples, they observed a tendency of inverse correlations between miR-138 
and H2AX expression. 
Based on previous findings that H2AX-deficient cells are sensitive to IR and exhibit DNA double-
strand break repair defects, the authors investigated whether miR-138 sensitized cells to IR and 
chemotherapy agents, as both radiotherapy and chemotherapy rely on the induction of DNA 
damage. They found that overexpression of miR-138 sensitized cells to DNA damaging 
chemotherapy agents and IR, resulting in a significantly higher number of chromosome breaks and 
mild defect in homologous recombination repair compared to control cells. Wang et al. showed that 
sensitization was not due to general cellular toxicity, but that miR-138 overexpression did appear to 
slow down cell growth without significantly affecting cell-cycle distribution. Perhaps it should come as 
no surprise then, that miR-138 allelic loss and downregulation has also been frequently associated 
with cancer (e.g., nasopharyngeal cancer, anaplastic thyroid carcinoma, metastatic head and neck 
squamous cell carcinoma, hepatocellular carcinoma). Therefore, Wang et al. propose miR-138 as a  
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novel cancer therapeutic and have presented a powerful approach to identify other miR-based 
therapies. 
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